Insider Trades207 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 1,500 | $524.99 | $123.3B | -9.00% | +33.97% | $787.5K | -3.20% | 10b5-1 | Stalk |
| Jul 2, 2026 | Sell | VRTX | Duncan Mckechnie | EVP, Chief Commercial Officer | 1,541 | $519.00 | $123.3B | -9.00% | +33.97% | $799.8K | -12.29% | 10b5-1 | Stalk |
| Jul 1, 2026 | Sell | VRTX | Joy Liu | EVP and Chief Legal Officer | 828 | $502.71 | $123.3B | -9.00% | +33.97% | $416.2K | -4.15% | 10b5-1 | Stalk |
| Jun 26, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 596 | $482.50 | $123.3B | -9.00% | +33.97% | $287.6K | -3.74% | 10b5-1 | Stalk |
| Jun 18, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 1,020 | $462.17 | $123.3B | -9.00% | +33.97% | $471.4K | -6.02% | 10b5-1 | Stalk |
| Jun 15, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 4,062 | $450.00 | $123.3B | -9.00% | +33.97% | $1.8M | -19.33% | 10b5-1 | Stalk |
| Jun 5, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 1,745 | $450.00 | $123.3B | -9.00% | +33.97% | $785.3K | -7.67% | 10b5-1 | Stalk |
| Jun 1, 2026 | Sell | VRTX | Joy Liu | EVP and Chief Legal Officer | 828 | $439.91 | $123.3B | -9.00% | +33.97% | $364.2K | -3.98% | 10b5-1 | Stalk |
| May 29, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 1,974 | $450.00 | $123.3B | -9.00% | +33.97% | $888.3K | -7.98% | 10b5-1 | Stalk |
| May 15, 2026 | Sell | VRTX | Mark E. Bunnage | EVP, Chief Scientific Officer | 33 | $453.45 | $123.3B | -9.00% | +33.97% | $15.0K | -0.45% | 10b5-1 | Stalk |
| May 15, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 1,354 | $453.45 | $123.3B | -9.00% | +33.97% | $614.0K | -5.19% | 10b5-1 | Stalk |
| May 12, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 6,988 | $450.00 | $123.3B | -9.00% | +33.97% | $3.1M | -21.13% | 10b5-1 | Stalk |
| May 1, 2026 | Sell | VRTX | Joy Liu | EVP and Chief Legal Officer | 1,104 | $425.02 | $123.3B | -9.00% | +33.97% | $469.2K | -5.06% | 10b5-1 | Stalk |
| Apr 1, 2026 | Sell | VRTX | Joy Liu | EVP and Chief Legal Officer | 978 | $449.17 | $123.3B | -9.00% | +33.97% | $439.3K | -4.29% | 10b5-1 | Stalk |
| Mar 27, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 2,329 | $450.95 | $123.3B | -9.00% | +33.97% | $1.1M | -6.58% | 10b5-1 | Stalk |
| Mar 13, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 2,329 | $481.79 | $123.3B | -9.00% | +33.97% | $1.1M | -6.17% | 10b5-1 | Stalk |
| Mar 11, 2026 | Sell | VRTX | Duncan Mckechnie | EVP, Chief Commercial Officer | 2,633 | $498.42 | $123.3B | -9.00% | +33.97% | $1.3M | -17.41% | 10b5-1 | Stalk |
| Mar 4, 2026 | Sell | VRTX | Duncan Mckechnie | EVP, Chief Commercial Officer | 2,437 | $475.30 | $123.3B | -9.00% | +33.97% | $1.2M | -13.88% | 10b5-1 | Stalk |
| Mar 2, 2026 | Sell | VRTX | Joy Liu | EVP and Chief Legal Officer | 892 | $495.96 | $123.3B | -9.00% | +33.97% | $442.4K | -3.76% | 10b5-1 | Stalk |
| Feb 27, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 2,329 | $480.31 | $123.3B | -9.00% | +33.97% | $1.1M | -5.81% | 10b5-1 | Stalk |
| Feb 27, 2026 | Sell | VRTX | Reshma Kewalramani | CEO & President | 40,000 | $493.47 | $123.3B | -9.00% | +33.97% | $19.7M | -2.41% | 10b5-1 | Stalk |
| Feb 26, 2026 | Sell | VRTX | Kristen Ambrose | SVP & Chief Accounting Officer | 357 | $483.36 | $123.3B | -9.00% | +33.97% | $172.6K | -5.11% | 10b5-1 | Stalk |
| Feb 24, 2026 | Sell | VRTX | Kristen Ambrose | SVP & Chief Accounting Officer | 769 | $485.47 | $123.3B | -9.00% | +33.97% | $373.3K | -5.14% | 10b5-1 | Stalk |
| Feb 24, 2026 | Sell | VRTX | Mark E. Bunnage | EVP, Chief Scientific Officer | 1,202 | $485.75 | $123.3B | -9.00% | +33.97% | $583.9K | -7.33% | 10b5-1 | Stalk |
| Feb 24, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 1,453 | $485.11 | $123.3B | -9.00% | +33.97% | $704.9K | -3.50% | — | Stalk |
| Feb 24, 2026 | Sell | VRTX | Charles F Jr Wagner | EVP, CO & FO | 1,744 | $485.11 | $123.3B | -9.00% | +33.97% | $846.0K | -3.57% | — | Stalk |
| Feb 24, 2026 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 1,887 | $485.28 | $123.3B | -9.00% | +33.97% | $915.7K | -1.97% | 10b5-1 | Stalk |
| Feb 24, 2026 | Sell | VRTX | Jonathan Biller | EVP and Chief Legal Officer | 2,089 | $485.67 | $123.3B | -9.00% | +33.97% | $1.0M | -6.88% | 10b5-1 | Stalk |
| Feb 24, 2026 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 2,295 | $485.47 | $123.3B | -9.00% | +33.97% | $1.1M | -5.76% | 10b5-1 | Stalk |
| Feb 24, 2026 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 3,364 | $485.79 | $123.3B | -9.00% | +33.97% | $1.6M | -2.89% | 10b5-1 | Stalk |
| Feb 24, 2026 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 3,547 | $485.11 | $123.3B | -9.00% | +33.97% | $1.7M | -9.25% | — | Stalk |
| Feb 24, 2026 | Sell | VRTX | Reshma Kewalramani | CEO & President | 4,981 | $485.11 | $123.3B | -9.00% | +33.97% | $2.4M | -3.48% | — | Stalk |
| Feb 24, 2026 | Sell | VRTX | Duncan Mckechnie | EVP, Chief Commercial Officer | 5,783 | $487.27 | $123.3B | -9.00% | +33.97% | $2.8M | -8.79% | 10b5-1 | Stalk |
| Feb 19, 2026 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 107,118 | $334.45 | $123.3B | -9.00% | +33.97% | $35.8M | -1.07% | 10b5-1 | Stalk |
| Feb 18, 2026 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 2,964 | $483.75 | $123.3B | -9.00% | +33.97% | $1.4M | -7.18% | — | Stalk |
| Feb 17, 2026 | Sell | VRTX | Duncan Mckechnie | EVP, Chief Commercial Officer | 1,148 | $483.75 | $123.3B | -9.00% | +33.97% | $555.3K | -4.69% | — | Stalk |
| Feb 17, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 1,912 | $483.75 | $123.3B | -9.00% | +33.97% | $924.9K | -4.40% | — | Stalk |
| Feb 17, 2026 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 2,140 | $483.75 | $123.3B | -9.00% | +33.97% | $1.0M | -3.01% | — | Stalk |
| Feb 17, 2026 | Sell | VRTX | Charles F Jr Wagner | EVP, CO & FO | 2,294 | $483.75 | $123.3B | -9.00% | +33.97% | $1.1M | -4.49% | — | Stalk |
| Feb 17, 2026 | Sell | VRTX | Kristen Ambrose | SVP & Chief Accounting Officer | 2,793 | $484.63 | $123.3B | -9.00% | +33.97% | $1.4M | -9.67% | 10b5-1 | Stalk |
| Feb 17, 2026 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 3,271 | $483.68 | $123.3B | -9.00% | +33.97% | $1.6M | -2.17% | 10b5-1 | Stalk |
| Feb 17, 2026 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 4,378 | $484.52 | $123.3B | -9.00% | +33.97% | $2.1M | -6.23% | 10b5-1 | Stalk |
| Feb 17, 2026 | Sell | VRTX | Mark E. Bunnage | EVP, Chief Scientific Officer | 4,729 | $484.18 | $123.3B | -9.00% | +33.97% | $2.3M | -13.52% | 10b5-1 | Stalk |
| Feb 17, 2026 | Sell | VRTX | Jonathan Biller | EVP and Chief Legal Officer | 5,225 | $484.06 | $123.3B | -9.00% | +33.97% | $2.5M | -9.10% | 10b5-1 | Stalk |
| Feb 17, 2026 | Sell | VRTX | Reshma Kewalramani | CEO & President | 6,554 | $483.75 | $123.3B | -9.00% | +33.97% | $3.2M | -4.37% | — | Stalk |
| Feb 13, 2026 | Sell | VRTX | Kristen Ambrose | SVP & Chief Accounting Officer | 1,393 | $487.76 | $123.3B | -9.00% | +33.97% | $679.4K | -13.76% | — | Stalk |
| Feb 13, 2026 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 1,903 | $487.76 | $123.3B | -9.00% | +33.97% | $928.2K | -8.63% | — | Stalk |
| Feb 13, 2026 | Sell | VRTX | Mark E. Bunnage | EVP, Chief Scientific Officer | 2,283 | $487.76 | $123.3B | -9.00% | +33.97% | $1.1M | -17.68% | — | Stalk |
| Feb 13, 2026 | Sell | VRTX | Duncan Mckechnie | EVP, Chief Commercial Officer | 2,283 | $487.76 | $123.3B | -9.00% | +33.97% | $1.1M | -10.47% | — | Stalk |
| Feb 13, 2026 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 3,548 | $487.76 | $123.3B | -9.00% | +33.97% | $1.7M | -5.15% | — | Stalk |
| Feb 13, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 3,804 | $487.76 | $123.3B | -9.00% | +33.97% | $1.9M | -9.09% | — | Stalk |
| Feb 13, 2026 | Sell | VRTX | Jonathan Biller | EVP and Chief Legal Officer | 3,981 | $490.55 | $123.3B | -9.00% | +33.97% | $2.0M | -10.30% | 10b5-1 | Stalk |
| Feb 13, 2026 | Sell | VRTX | Charles F Jr Wagner | EVP, CO & FO | 4,565 | $487.76 | $123.3B | -9.00% | +33.97% | $2.2M | -9.46% | — | Stalk |
| Feb 13, 2026 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 5,304 | $491.22 | $123.3B | -9.00% | +33.97% | $2.6M | -5.35% | 10b5-1 | Stalk |
| Feb 13, 2026 | Sell | VRTX | Reshma Kewalramani | CEO & President | 13,041 | $487.76 | $123.3B | -9.00% | +33.97% | $6.4M | -8.90% | — | Stalk |
| Feb 10, 2026 | Sell | VRTX | Duncan Mckechnie | EVP, Chief Commercial Officer | 1,127 | $468.41 | $123.3B | -9.00% | +33.97% | $527.9K | -4.91% | — | Stalk |
| Feb 10, 2026 | Sell | VRTX | Kristen Ambrose | SVP & Chief Accounting Officer | 1,968 | $462.83 | $123.3B | -9.00% | +33.97% | $910.9K | -8.34% | 10b5-1 | Stalk |
| Feb 10, 2026 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 2,057 | $468.41 | $123.3B | -9.00% | +33.97% | $963.5K | -2.90% | — | Stalk |
| Feb 10, 2026 | Sell | VRTX | Carmen Bozic | EVP and CMO | 2,145 | $468.41 | $123.3B | -9.00% | +33.97% | $1.0M | -4.87% | — | Stalk |
| Feb 10, 2026 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 2,623 | $463.08 | $123.3B | -9.00% | +33.97% | $1.2M | -5.41% | 10b5-1 | Stalk |
| Feb 10, 2026 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 2,606 | $466.98 | $123.3B | -9.00% | +33.97% | $1.2M | -2.46% | 10b5-1 | Stalk |
| Feb 10, 2026 | Sell | VRTX | Charles F Jr Wagner | EVP, CO & FO | 3,045 | $468.41 | $123.3B | -9.00% | +33.97% | $1.4M | -5.93% | — | Stalk |
| Feb 10, 2026 | Sell | VRTX | Mark E. Bunnage | EVP, Chief Scientific Officer | 3,148 | $463.29 | $123.3B | -9.00% | +33.97% | $1.5M | -10.16% | 10b5-1 | Stalk |
| Feb 10, 2026 | Sell | VRTX | Jonathan Biller | EVP and Chief Legal Officer | 3,555 | $464.09 | $123.3B | -9.00% | +33.97% | $1.6M | -7.54% | 10b5-1 | Stalk |
| Feb 10, 2026 | Sell | VRTX | Reshma Kewalramani | CEO & President | 8,297 | $468.41 | $123.3B | -9.00% | +33.97% | $3.9M | -5.36% | — | Stalk |
| Jan 7, 2026 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 4,500 | $474.99 | $123.3B | -9.00% | +33.97% | $2.1M | -9.62% | 10b5-1 | Stalk |
| Jan 6, 2026 | Sell | VRTX | Charles F Jr Wagner | EVP, CO & FO | 19,064 | $325.19 | $123.3B | -9.00% | +33.97% | $6.2M | +0.00% | 10b5-1 | Stalk |
| Dec 3, 2025 | Sell | VRTX | Jonathan Biller | EVP and Chief Legal Officer | 347 | $449.00 | $123.3B | -9.00% | +33.97% | $155.8K | -2.22% | 10b5-1 | Stalk |
| Dec 3, 2025 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 4,500 | $449.99 | $123.3B | -9.00% | +33.97% | $2.0M | -8.77% | 10b5-1 | Stalk |
| Dec 3, 2025 | Sell | VRTX | Charles F Jr Wagner | EVP, CO & FO | 14,000 | $456.00 | $123.3B | -9.00% | +33.97% | $6.4M | -14.52% | 10b5-1 | Stalk |
| Dec 3, 2025 | Buy | VRTX | Jeffrey M Leiden | Executive Chairman | 127,563 | $267.86 | $123.3B | -9.00% | +33.97% | $34.2M | +0.00% | 10b5-1 | Stalk |
| Nov 17, 2025 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 2,500 | $434.58 | $123.3B | -9.00% | +33.97% | $1.1M | -12.92% | 10b5-1 | Stalk |
| Nov 13, 2025 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 146,584 | $264.60 | $123.3B | -9.00% | +33.97% | $38.8M | +0.00% | 10b5-1 | Stalk |
| Oct 1, 2025 | Sell | VRTX | Jonathan Biller | EVP and Chief Legal Officer | 1,953 | $401.50 | $123.3B | -9.00% | +33.97% | $784.1K | -5.75% | 10b5-1 | Stalk |
| Aug 6, 2025 | Buy | VRTX | Reshma Kewalramani | CEO & President | 10,000 | $389.58 | $123.3B | -9.00% | +33.97% | $3.9M | +4.62% | — | Stalk |
| Jul 1, 2025 | Sell | VRTX | Stuart A Arbuckle | EVP, COO | 37,243 | $450.23 | $123.3B | -9.00% | +33.97% | $16.8M | -37.02% | — | Stalk |
| May 15, 2025 | Sell | VRTX | David Altshuler | EVP, Chief Scientific Officer | 52 | $424.69 | $123.3B | -9.00% | +33.97% | $22.1K | -0.22% | 10b5-1 | Stalk |
| Mar 13, 2025 | Sell | VRTX | David Altshuler | EVP, Chief Scientific Officer | 3,231 | $510.00 | $123.3B | -9.00% | +33.97% | $1.6M | -12.19% | 10b5-1 | Stalk |
| Mar 10, 2025 | Sell | VRTX | David Altshuler | EVP, Chief Scientific Officer | 3,231 | $500.00 | $123.3B | -9.00% | +33.97% | $1.6M | -10.86% | 10b5-1 | Stalk |
| Mar 10, 2025 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 3,242 | $499.99 | $123.3B | -9.00% | +33.97% | $1.6M | -5.95% | 10b5-1 | Stalk |
| Mar 10, 2025 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 3,298 | $500.00 | $123.3B | -9.00% | +33.97% | $1.6M | -6.00% | 10b5-1 | Stalk |
| Mar 4, 2025 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 4,058 | $485.49 | $123.3B | -9.00% | +33.97% | $2.0M | -6.93% | 10b5-1 | Stalk |
| Mar 3, 2025 | Sell | VRTX | David Altshuler | EVP, Chief Scientific Officer | 3,231 | $490.00 | $123.3B | -9.00% | +33.97% | $1.6M | -9.80% | 10b5-1 | Stalk |
| Feb 26, 2025 | Sell | VRTX | Kristen Ambrose | SVP & Chief Accounting Officer | 1,241 | $479.61 | $123.3B | -9.00% | +33.97% | $595.2K | -13.66% | — | Stalk |
| Feb 26, 2025 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 3,703 | $479.61 | $123.3B | -9.00% | +33.97% | $1.8M | -5.13% | — | Stalk |
| Feb 26, 2025 | Sell | VRTX | Carmen Bozic | EVP and CMO | 4,962 | $479.61 | $123.3B | -9.00% | +33.97% | $2.4M | -13.19% | — | Stalk |
| Feb 26, 2025 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 4,962 | $479.61 | $123.3B | -9.00% | +33.97% | $2.4M | -8.28% | — | Stalk |
| Feb 26, 2025 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 5,132 | $477.41 | $123.3B | -9.00% | +33.97% | $2.5M | -11.04% | 10b5-1 | Stalk |
| Feb 26, 2025 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 5,492 | $479.20 | $123.3B | -9.00% | +33.97% | $2.6M | -4.46% | 10b5-1 | Stalk |
| Feb 26, 2025 | Sell | VRTX | Stuart A Arbuckle | EVP, COO | 7,071 | $479.61 | $123.3B | -9.00% | +33.97% | $3.4M | -10.10% | — | Stalk |
| Feb 26, 2025 | Sell | VRTX | David Altshuler | EVP, Chief Scientific Officer | 7,226 | $479.68 | $123.3B | -9.00% | +33.97% | $3.5M | -9.71% | 10b5-1 | Stalk |
| Feb 26, 2025 | Sell | VRTX | Reshma Kewalramani | CEO & President | 14,079 | $479.61 | $123.3B | -9.00% | +33.97% | $6.8M | -11.73% | — | Stalk |
| Feb 24, 2025 | Sell | VRTX | Kristen Ambrose | SVP & Chief Accounting Officer | 1,712 | $482.08 | $123.3B | -9.00% | +33.97% | $825.3K | -8.24% | 10b5-1 | Stalk |
| Feb 24, 2025 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 2,470 | $483.28 | $123.3B | -9.00% | +33.97% | $1.2M | -3.31% | — | Stalk |
| Feb 24, 2025 | Sell | VRTX | Carmen Bozic | EVP and CMO | 3,310 | $483.28 | $123.3B | -9.00% | +33.97% | $1.6M | -8.08% | — | Stalk |
| Feb 24, 2025 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 3,310 | $483.28 | $123.3B | -9.00% | +33.97% | $1.6M | -5.23% | — | Stalk |
| Feb 24, 2025 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 3,423 | $482.08 | $123.3B | -9.00% | +33.97% | $1.7M | -6.32% | 10b5-1 | Stalk |
| Feb 24, 2025 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 3,664 | $483.05 | $123.3B | -9.00% | +33.97% | $1.8M | -2.77% | 10b5-1 | Stalk |
| Feb 24, 2025 | Sell | VRTX | Stuart A Arbuckle | EVP, COO | 4,716 | $483.28 | $123.3B | -9.00% | +33.97% | $2.3M | -6.31% | — | Stalk |
| Feb 24, 2025 | Sell | VRTX | David Altshuler | EVP, Chief Scientific Officer | 4,819 | $482.87 | $123.3B | -9.00% | +33.97% | $2.3M | -5.60% | 10b5-1 | Stalk |
| Feb 24, 2025 | Sell | VRTX | Reshma Kewalramani | CEO & President | 9,386 | $483.28 | $123.3B | -9.00% | +33.97% | $4.5M | -7.25% | — | Stalk |
| Feb 20, 2025 | Sell | VRTX | David Altshuler | EVP, Chief Scientific Officer | 1,111 | $480.00 | $123.3B | -9.00% | +33.97% | $533.3K | -2.41% | 10b5-1 | Stalk |
| Feb 14, 2025 | Sell | VRTX | Kristen Ambrose | SVP & Chief Accounting Officer | 1,235 | $458.90 | $123.3B | -9.00% | +33.97% | $566.7K | -5.25% | 10b5-1 | Stalk |
| Feb 14, 2025 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 1,529 | $463.46 | $123.3B | -9.00% | +33.97% | $708.6K | -5.19% | — | Stalk |
| Feb 14, 2025 | Sell | VRTX | Carmen Bozic | EVP and CMO | 1,912 | $463.46 | $123.3B | -9.00% | +33.97% | $886.1K | -4.46% | — | Stalk |
| Feb 14, 2025 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 2,139 | $463.46 | $123.3B | -9.00% | +33.97% | $991.3K | -2.79% | — | Stalk |
| Feb 14, 2025 | Sell | VRTX | David Altshuler | EVP, Chief Scientific Officer | 2,293 | $463.46 | $123.3B | -9.00% | +33.97% | $1.1M | -4.74% | — | Stalk |
| Feb 14, 2025 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 2,293 | $463.46 | $123.3B | -9.00% | +33.97% | $1.1M | -3.50% | — | Stalk |
| Feb 14, 2025 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 2,537 | $462.65 | $123.3B | -9.00% | +33.97% | $1.2M | -1.84% | 10b5-1 | Stalk |
| Feb 14, 2025 | Sell | VRTX | Stuart A Arbuckle | EVP, COO | 2,724 | $463.46 | $123.3B | -9.00% | +33.97% | $1.3M | -3.52% | — | Stalk |
| Feb 14, 2025 | Sell | VRTX | Jonathan Biller | EVP and Chief Legal Officer | 3,161 | $459.06 | $123.3B | -9.00% | +33.97% | $1.5M | -7.90% | 10b5-1 | Stalk |
| Feb 14, 2025 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 6,066 | $463.46 | $123.3B | -9.00% | +33.97% | $2.8M | -20.16% | — | Stalk |
| Feb 14, 2025 | Sell | VRTX | Reshma Kewalramani | CEO & President | 6,553 | $463.46 | $123.3B | -9.00% | +33.97% | $3.0M | -4.82% | — | Stalk |
| Feb 13, 2025 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 2,525 | $450.83 | $123.3B | -9.00% | +33.97% | $1.1M | -7.74% | — | Stalk |
| Feb 10, 2025 | Sell | VRTX | Kristen Ambrose | SVP & Chief Accounting Officer | 1,967 | $462.28 | $123.3B | -9.00% | +33.97% | $909.3K | -8.46% | 10b5-1 | Stalk |
| Feb 10, 2025 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 2,056 | $467.98 | $123.3B | -9.00% | +33.97% | $962.2K | -2.83% | — | Stalk |
| Feb 10, 2025 | Sell | VRTX | David Altshuler | EVP, Chief Scientific Officer | 2,142 | $467.98 | $123.3B | -9.00% | +33.97% | $1.0M | -4.73% | — | Stalk |
| Feb 10, 2025 | Sell | VRTX | Carmen Bozic | EVP and CMO | 2,142 | $467.98 | $123.3B | -9.00% | +33.97% | $1.0M | -5.43% | — | Stalk |
| Feb 10, 2025 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 2,453 | $466.95 | $123.3B | -9.00% | +33.97% | $1.1M | -1.88% | 10b5-1 | Stalk |
| Feb 10, 2025 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 2,623 | $462.55 | $123.3B | -9.00% | +33.97% | $1.2M | -5.16% | 10b5-1 | Stalk |
| Feb 10, 2025 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 2,649 | $467.98 | $123.3B | -9.00% | +33.97% | $1.2M | -4.31% | — | Stalk |
| Feb 10, 2025 | Sell | VRTX | Stuart A Arbuckle | EVP, COO | 3,220 | $467.98 | $123.3B | -9.00% | +33.97% | $1.5M | -4.43% | — | Stalk |
| Feb 10, 2025 | Sell | VRTX | Jonathan Biller | EVP and Chief Legal Officer | 5,065 | $462.48 | $123.3B | -9.00% | +33.97% | $2.3M | -12.31% | 10b5-1 | Stalk |
| Feb 10, 2025 | Sell | VRTX | Reshma Kewalramani | CEO & President | 8,300 | $467.98 | $123.3B | -9.00% | +33.97% | $3.9M | -6.63% | — | Stalk |
| Nov 15, 2024 | Sell | VRTX | David Altshuler | EVP, Chief Scientific Officer | 15 | $478.56 | $123.3B | -9.00% | +33.97% | $7.2K | -0.06% | 10b5-1 | Stalk |
| Nov 11, 2024 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 3,000 | $518.27 | $123.3B | -9.00% | +33.97% | $1.6M | -6.36% | 10b5-1 | Stalk |
| Nov 8, 2024 | Sell | VRTX | Reshma Kewalramani | CEO & President | 15,198 | $515.00 | $123.3B | -9.00% | +33.97% | $7.8M | -16.71% | 10b5-1 | Stalk |
| Oct 1, 2024 | Sell | VRTX | Jonathan Biller | EVP and Chief Legal Officer | 1,629 | $463.66 | $123.3B | -9.00% | +33.97% | $755.3K | -4.53% | 10b5-1 | Stalk |
| Aug 30, 2024 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 3,784 | $499.00 | $123.3B | -9.00% | +33.97% | $1.9M | -27.46% | 10b5-1 | Stalk |
| Aug 7, 2024 | Sell | VRTX | Carmen Bozic | EVP and CMO | 2,280 | $476.75 | $123.3B | -9.00% | +33.97% | $1.1M | -8.93% | 10b5-1 | Stalk |
| Jul 30, 2024 | Sell | VRTX | Reshma Kewalramani | CEO & President | 15,202 | $505.00 | $123.3B | -9.00% | +33.97% | $7.7M | -14.32% | 10b5-1 | Stalk |
| Jul 24, 2024 | Sell | VRTX | Carmen Bozic | EVP and CMO | 2,280 | $488.46 | $123.3B | -9.00% | +33.97% | $1.1M | -8.20% | 10b5-1 | Stalk |
| Jul 22, 2024 | Sell | VRTX | Reshma Kewalramani | CEO & President | 15,202 | $497.00 | $123.3B | -9.00% | +33.97% | $7.6M | -12.52% | 10b5-1 | Stalk |
| Jul 10, 2024 | Sell | VRTX | Carmen Bozic | EVP and CMO | 2,280 | $487.34 | $123.3B | -9.00% | +33.97% | $1.1M | -7.58% | 10b5-1 | Stalk |
| Jun 26, 2024 | Sell | VRTX | Carmen Bozic | EVP and CMO | 2,280 | $471.72 | $123.3B | -9.00% | +33.97% | $1.1M | -7.04% | 10b5-1 | Stalk |
| Jun 12, 2024 | Sell | VRTX | Carmen Bozic | EVP and CMO | 2,280 | $478.00 | $123.3B | -9.00% | +33.97% | $1.1M | -6.58% | 10b5-1 | Stalk |
| Jun 11, 2024 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 14,112 | $479.91 | $123.3B | -9.00% | +33.97% | $6.8M | -26.45% | 10b5-1 | Stalk |
| Jun 5, 2024 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 4,600 | $483.04 | $123.3B | -9.00% | +33.97% | $2.2M | -100.00% | — | Stalk |
| Jun 3, 2024 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 2,175 | $460.00 | $123.3B | -9.00% | +33.97% | $1.0M | -4.24% | 10b5-1 | Stalk |
| Jun 3, 2024 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 3,250 | $460.00 | $123.3B | -9.00% | +33.97% | $1.5M | -6.45% | 10b5-1 | Stalk |
| May 30, 2024 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 4,600 | $441.99 | $123.3B | -9.00% | +33.97% | $2.0M | -4.20% | 10b5-1 | Stalk |
| May 29, 2024 | Sell | VRTX | Carmen Bozic | EVP and CMO | 2,280 | $445.56 | $123.3B | -9.00% | +33.97% | $1.0M | -6.17% | 10b5-1 | Stalk |
| May 28, 2024 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 3,250 | $454.79 | $123.3B | -9.00% | +33.97% | $1.5M | -6.06% | 10b5-1 | Stalk |
| May 24, 2024 | Sell | VRTX | Reshma Kewalramani | CEO & President | 3,130 | $322.26 | $123.3B | -9.00% | +33.97% | $1.0M | +0.00% | 10b5-1 | Stalk |
| May 20, 2024 | Sell | VRTX | Reshma Kewalramani | CEO & President | 15,202 | $447.00 | $123.3B | -9.00% | +33.97% | $6.8M | -11.13% | 10b5-1 | Stalk |
| May 15, 2024 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 32 | $430.93 | $123.3B | -9.00% | +33.97% | $13.8K | -0.06% | 10b5-1 | Stalk |
| May 15, 2024 | Sell | VRTX | David Altshuler | EVP, Chief Scientific Officer | 54 | $430.93 | $123.3B | -9.00% | +33.97% | $23.3K | -0.21% | 10b5-1 | Stalk |
| May 15, 2024 | Sell | VRTX | Stuart A Arbuckle | EVP, COO | 69 | $430.93 | $123.3B | -9.00% | +33.97% | $29.7K | -0.14% | 10b5-1 | Stalk |
| Apr 1, 2024 | Sell | VRTX | Kristen Ambrose | SVP & Chief Accounting Officer | 465 | $418.56 | $123.3B | -9.00% | +33.97% | $194.6K | -2.96% | 10b5-1 | Stalk |
| Feb 23, 2024 | Sell | VRTX | Kristen Ambrose | SVP & Chief Accounting Officer | 1,711 | $428.65 | $123.3B | -9.00% | +33.97% | $733.4K | -9.24% | 10b5-1 | Stalk |
| Feb 23, 2024 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 2,537 | $429.67 | $123.3B | -9.00% | +33.97% | $1.1M | -7.17% | 10b5-1 | Stalk |
| Feb 23, 2024 | Sell | VRTX | Carmen Bozic | EVP and CMO | 3,309 | $431.79 | $123.3B | -9.00% | +33.97% | $1.4M | -8.22% | — | Stalk |
| Feb 23, 2024 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 3,309 | $431.79 | $123.3B | -9.00% | +33.97% | $1.4M | -5.82% | — | Stalk |
| Feb 23, 2024 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 3,663 | $431.20 | $123.3B | -9.00% | +33.97% | $1.6M | -3.17% | 10b5-1 | Stalk |
| Feb 23, 2024 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 5,473 | $428.45 | $123.3B | -9.00% | +33.97% | $2.3M | -4.59% | 10b5-1 | Stalk |
| Feb 23, 2024 | Sell | VRTX | David Altshuler | EVP, Global Research and CSO | 8,209 | $428.65 | $123.3B | -9.00% | +33.97% | $3.5M | -12.81% | 10b5-1 | Stalk |
| Feb 23, 2024 | Sell | VRTX | Reshma Kewalramani | CEO & President | 9,386 | $431.79 | $123.3B | -9.00% | +33.97% | $4.1M | -6.43% | — | Stalk |
| Feb 23, 2024 | Sell | VRTX | Stuart A Arbuckle | EVP, COO | 9,748 | $428.65 | $123.3B | -9.00% | +33.97% | $4.2M | -8.54% | 10b5-1 | Stalk |
| Feb 21, 2024 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 360 | $421.77 | $123.3B | -9.00% | +33.97% | $151.8K | -0.60% | 10b5-1 | Stalk |
| Feb 21, 2024 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 1,201 | $421.77 | $123.3B | -9.00% | +33.97% | $506.5K | -6.09% | 10b5-1 | Stalk |
| Feb 21, 2024 | Sell | VRTX | David Altshuler | EVP, Global Research and CSO | 3,002 | $421.77 | $123.3B | -9.00% | +33.97% | $1.3M | -8.11% | 10b5-1 | Stalk |
| Feb 21, 2024 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 3,191 | $421.77 | $123.3B | -9.00% | +33.97% | $1.3M | -4.99% | 10b5-1 | Stalk |
| Feb 21, 2024 | Sell | VRTX | Stuart A Arbuckle | EVP, COO | 3,603 | $421.77 | $123.3B | -9.00% | +33.97% | $1.5M | -5.72% | 10b5-1 | Stalk |
| Feb 20, 2024 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 4,118 | $420.58 | $123.3B | -9.00% | +33.97% | $1.7M | -23.01% | — | Stalk |
| Feb 16, 2024 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 3,427 | $422.13 | $123.3B | -9.00% | +33.97% | $1.4M | -5.25% | 10b5-1 | Stalk |
| Feb 16, 2024 | Sell | VRTX | Carmen Bozic | EVP and CMO | 6,562 | $422.54 | $123.3B | -9.00% | +33.97% | $2.8M | -7.30% | — | Stalk |
| Feb 16, 2024 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 6,562 | $422.54 | $123.3B | -9.00% | +33.97% | $2.8M | -5.33% | — | Stalk |
| Feb 16, 2024 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 8,352 | $422.44 | $123.3B | -9.00% | +33.97% | $3.5M | -4.35% | 10b5-1 | Stalk |
| Feb 16, 2024 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 10,375 | $421.82 | $123.3B | -9.00% | +33.97% | $4.4M | -4.86% | 10b5-1 | Stalk |
| Feb 16, 2024 | Sell | VRTX | David Altshuler | EVP, Global Research and CSO | 10,564 | $421.88 | $123.3B | -9.00% | +33.97% | $4.5M | -7.98% | 10b5-1 | Stalk |
| Feb 16, 2024 | Sell | VRTX | Stuart A Arbuckle | EVP, COO | 12,676 | $421.88 | $123.3B | -9.00% | +33.97% | $5.3M | -5.90% | 10b5-1 | Stalk |
| Feb 16, 2024 | Sell | VRTX | Reshma Kewalramani | CEO & President | 16,378 | $422.54 | $123.3B | -9.00% | +33.97% | $6.9M | -5.20% | — | Stalk |
| Feb 14, 2024 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 9,011 | $419.10 | $123.3B | -9.00% | +33.97% | $3.8M | -18.22% | 10b5-1 | Stalk |
| Feb 12, 2024 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 3,393 | $419.42 | $123.3B | -9.00% | +33.97% | $1.4M | -3.93% | 10b5-1 | Stalk |
| Feb 9, 2024 | Sell | VRTX | Edward Morrow Iii Atkinson | EVP, Chief Technical Ops. Off. | 1,745 | $421.43 | $123.3B | -9.00% | +33.97% | $735.4K | -3.57% | 10b5-1 | Stalk |
| Feb 9, 2024 | Sell | VRTX | Kristen Ambrose | SVP & Chief Accounting Officer | 1,965 | $420.99 | $123.3B | -9.00% | +33.97% | $827.2K | -8.66% | 10b5-1 | Stalk |
| Feb 9, 2024 | Sell | VRTX | Carmen Bozic | EVP and CMO | 2,100 | $422.74 | $123.3B | -9.00% | +33.97% | $887.8K | -4.29% | — | Stalk |
| Feb 9, 2024 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 2,414 | $422.41 | $123.3B | -9.00% | +33.97% | $1.0M | -1.74% | 10b5-1 | Stalk |
| Feb 9, 2024 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 2,607 | $422.74 | $123.3B | -9.00% | +33.97% | $1.1M | -3.95% | — | Stalk |
| Feb 9, 2024 | Sell | VRTX | Jonathan Biller | EVP and Chief Legal Officer | 3,326 | $420.67 | $123.3B | -9.00% | +33.97% | $1.4M | -7.99% | 10b5-1 | Stalk |
| Feb 9, 2024 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 5,244 | $421.20 | $123.3B | -9.00% | +33.97% | $2.2M | -3.34% | 10b5-1 | Stalk |
| Feb 9, 2024 | Sell | VRTX | David Altshuler | EVP, Global Research and CSO | 5,244 | $421.24 | $123.3B | -9.00% | +33.97% | $2.2M | -5.06% | 10b5-1 | Stalk |
| Feb 9, 2024 | Sell | VRTX | Stuart A Arbuckle | EVP, COO | 7,472 | $421.30 | $123.3B | -9.00% | +33.97% | $3.1M | -4.58% | 10b5-1 | Stalk |
| Feb 9, 2024 | Sell | VRTX | Reshma Kewalramani | CEO & President | 8,255 | $422.74 | $123.3B | -9.00% | +33.97% | $3.5M | -4.84% | — | Stalk |
| Feb 8, 2024 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 10,746 | $422.49 | $123.3B | -9.00% | +33.97% | $4.5M | -13.54% | — | Stalk |
| Jan 8, 2024 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 6,648 | $419.07 | $123.3B | -9.00% | +33.97% | $2.8M | -73.29% | 10b5-1 | Stalk |
| Jan 2, 2024 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 3,000 | $405.00 | $123.3B | -9.00% | +33.97% | $1.2M | -6.42% | 10b5-1 | Stalk |
| Dec 15, 2023 | Sell | VRTX | Reshma Kewalramani | CEO & President | 34,270 | $294.41 | $123.3B | -9.00% | +33.97% | $10.1M | +0.00% | 10b5-1 | Stalk |
| Dec 13, 2023 | Sell | VRTX | Reshma Kewalramani | CEO & President | 5,098 | $397.00 | $123.3B | -9.00% | +33.97% | $2.0M | -4.48% | 10b5-1 | Stalk |
| Dec 13, 2023 | Sell | VRTX | Stuart A Arbuckle | EVP, COO | 17,206 | $293.26 | $123.3B | -9.00% | +33.97% | $5.0M | +0.00% | 10b5-1 | Stalk |
| Dec 13, 2023 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 13,354 | $399.42 | $123.3B | -9.00% | +33.97% | $5.3M | -42.26% | 10b5-1 | Stalk |
| Nov 20, 2023 | Sell | VRTX | Charles F Jr Wagner | EVP & Chief Financial Officer | 3,000 | $349.88 | $123.3B | -9.00% | +33.97% | $1.0M | -6.04% | 10b5-1 | Stalk |
| Nov 15, 2023 | Sell | VRTX | David Altshuler | EVP, Global Research and CSO | 19 | $369.92 | $123.3B | -9.00% | +33.97% | $7.0K | -0.06% | 10b5-1 | Stalk |
| Nov 15, 2023 | Sell | VRTX | Amit Sachdev | EVP Chief Patient & Ext Af Off | 35 | $369.92 | $123.3B | -9.00% | +33.97% | $12.9K | -0.06% | 10b5-1 | Stalk |
| Nov 14, 2023 | Sell | VRTX | Carmen Bozic | EVP and CMO | 5,650 | $380.82 | $123.3B | -9.00% | +33.97% | $2.2M | -16.17% | 10b5-1 | Stalk |
| Nov 13, 2023 | Sell | VRTX | Reshma Kewalramani | CEO & President | 5,097 | $377.00 | $123.3B | -9.00% | +33.97% | $1.9M | -4.29% | 10b5-1 | Stalk |
| Oct 31, 2023 | Sell | VRTX | Carmen Bozic | EVP and CMO | 5,651 | $355.92 | $123.3B | -9.00% | +33.97% | $2.0M | -13.92% | 10b5-1 | Stalk |
| Oct 17, 2023 | Sell | VRTX | Carmen Bozic | EVP and CMO | 5,651 | $373.25 | $123.3B | -9.00% | +33.97% | $2.1M | -12.22% | 10b5-1 | Stalk |
| Oct 16, 2023 | Sell | VRTX | Jeffrey M Leiden | Executive Chairman | 12,962 | $374.00 | $123.3B | -9.00% | +33.97% | $4.8M | -36.63% | 10b5-1 | Stalk |
| Oct 3, 2023 | Sell | VRTX | Carmen Bozic | EVP and CMO | 5,651 | $345.28 | $123.3B | -9.00% | +33.97% | $2.0M | -10.89% | 10b5-1 | Stalk |
| Sep 29, 2023 | Sell | VRTX | Jonathan Biller | EVP and Chief Legal Officer | 1,018 | $348.35 | $123.3B | -9.00% | +33.97% | $354.6K | -4.47% | 10b5-1 | Stalk |
| Sep 19, 2023 | Sell | VRTX | Carmen Bozic | EVP and CMO | 5,651 | $351.00 | $123.3B | -9.00% | +33.97% | $2.0M | -9.82% | 10b5-1 | Stalk |
| Sep 5, 2023 | Sell | VRTX | Carmen Bozic | EVP and CMO | 5,651 | $352.66 | $123.3B | -9.00% | +33.97% | $2.0M | -8.94% | 10b5-1 | Stalk |
| Aug 23, 2023 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 2,500 | $355.00 | $123.3B | -9.00% | +33.97% | $887.5K | -4.89% | 10b5-1 | Stalk |
| Aug 10, 2023 | Sell | VRTX | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 5,750 | $345.79 | $123.3B | -9.00% | +33.97% | $2.0M | -10.11% | 10b5-1 | Stalk |
| Aug 10, 2023 | Sell | VRTX | Amit Sachdev | EVP, Chief Patient Officer | 10,031 | $350.00 | $123.3B | -9.00% | +33.97% | $3.5M | -14.57% | 10b5-1 | Stalk |
| Aug 9, 2023 | Sell | VRTX | David Altshuler | EVP, Global Research and CSO | 63 | $345.51 | $123.3B | -9.00% | +33.97% | $21.8K | -0.20% | 10b5-1 | Stalk |